Merck expects oncology king Keytruda to face IRA 'price setting' process starting in 2026
The government price negotiations affecting Keytruda wouldn't take effect until 2028, Merck said in its annual securities filing. That year will also see a key patent loss for the drug.
The government price negotiations affecting Keytruda wouldn't take effect until 2028, Merck said in its annual securities filing. That year will also see a key patent loss for the drug.
